Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 237

1.

Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients.

Yeo W, Ho WM, Hui P, Chan PK, Lam KC, Lee JJ, Johnson PJ.

Breast Cancer Res Treat. 2004 Dec;88(3):209-15.

PMID:
15609123
2.

Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine.

Yeo W, Hui EP, Chan AT, Ho WM, Lam KC, Chan PK, Mok TS, Lee JJ, Mo FK, Johnson PJ.

Am J Clin Oncol. 2005 Aug;28(4):379-84.

PMID:
16062080
3.

Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.

Yeo W, Chan PK, Ho WM, Zee B, Lam KC, Lei KI, Chan AT, Mok TS, Lee JJ, Leung TW, Zhong S, Johnson PJ.

J Clin Oncol. 2004 Mar 1;22(5):927-34.

PMID:
14990649
4.

A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy?

Long M, Jia W, Li S, Jin L, Wu J, Rao N, Feng H, Chen K, Deng H, Liu F, Su F, Song E.

Breast Cancer Res Treat. 2011 Jun;127(3):705-12. doi: 10.1007/s10549-011-1455-9. Epub 2011 Mar 29.

PMID:
21445574
5.

Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.

Cil T, Altintas A, Pasa S, Bayan K, Ozekinci T, Isikdogan A.

Leuk Lymphoma. 2008 May;49(5):939-47. doi: 10.1080/10428190801975568.

PMID:
18464113
6.
7.

Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma.

Li YH, He YF, Jiang WQ, Wang FH, Lin XB, Zhang L, Xia ZJ, Sun XF, Huang HQ, Lin TY, He YJ, Guan ZZ.

Cancer. 2006 Mar 15;106(6):1320-5.

8.

Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with Lamivudine.

Simpson ND, Simpson PW, Ahmed AM, Nguyen MH, Garcia G, Keeffe EB, Ahmed A.

J Clin Gastroenterol. 2003 Jul;37(1):68-71.

PMID:
12811213
9.

Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients.

Lim LL, Wai CT, Lee YM, Kong HL, Lim R, Koay E, Lim SG.

Aliment Pharmacol Ther. 2002 Nov;16(11):1939-44.

10.

Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors.

Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, Hui P, Leung NW, Zee B, Johnson PJ.

J Med Virol. 2000 Nov;62(3):299-307.

PMID:
11055239
11.

Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies.

Idilman R, Arat M, Soydan E, Törüner M, Soykan I, Akbulut H, Arslan O, Ozcan M, Türkyilmaz AR, Bozdayi M, Karayalçin S, Van Thiel DH, Ozden A, Beksaç M, Akan H.

J Viral Hepat. 2004 Mar;11(2):141-7.

PMID:
14996349
12.

Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy.

Yeo W, Steinberg JL, Tam JS, Chan PK, Leung NW, Lam KC, Mok TS, Johnson PJ.

J Med Virol. 1999 Nov;59(3):263-9.

PMID:
10502254
13.

Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role.

Steinberg JL, Yeo W, Zhong S, Chan JY, Tam JS, Chan PK, Leung NW, Johnson PJ.

J Med Virol. 2000 Mar;60(3):249-55.

PMID:
10630955
14.
15.

Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study.

Yeo W, Chan PK, Hui P, Ho WM, Lam KC, Kwan WH, Zhong S, Johnson PJ.

J Med Virol. 2003 Aug;70(4):553-61.

PMID:
12794717
16.

Hepatitis B reactivation during adjuvant anthracycline-based chemotherapy in patients with breast cancer: a single institution's experience.

Kim MK, Ahn JH, Kim SB, Im YS, Lee SI, Ahn SH, Son BH, Gong G, Kim HH, Kim WK.

Korean J Intern Med. 2007 Dec;22(4):237-43.

17.

Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy.

Yun J, Kim KH, Kang ES, Gwak GY, Choi MS, Lee JE, Nam SJ, Yang JH, Park YH, Ahn JS, Im YH.

Br J Cancer. 2011 Feb 15;104(4):559-63. doi: 10.1038/bjc.2011.4. Epub 2011 Feb 1.

18.

High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy.

Zhong S, Yeo W, Schroder C, Chan PK, Wong WL, Ho WM, Mo F, Zee B, Johnson PJ.

J Viral Hepat. 2004 Jan;11(1):55-9.

PMID:
14738558
19.
20.

Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy.

Leaw SJ, Yen CJ, Huang WT, Chen TY, Su WC, Tsao CJ.

Ann Hematol. 2004 May;83(5):270-5. Epub 2003 Dec 5.

PMID:
15060745

Supplemental Content

Support Center